Sherwin Isenberg
Gerber Professor
Ophthalmology
Los Angeles Biomedical Research Institute
United States of America
Biography
Dr. Isenberg is developing a conjunctival tissue gas monitor to measure all blood gases. His goal is to reduce blindness in newborns caused by Retinopathy of Prematurity by better controlling their oxygen and other gases. The treatment can also be used in emergency rooms, operating rooms, intensive care units and on the battlefield to direct care and potentially save lives. Additionally, Dr. Isenberg is using povidone-iodine ophthalmic solution to prevent and treat trachoma which blinds more than ten million people. This prospective trial would be conducted in Ethiopia. It is the culmination of our numerous studies which have proven the eye drop effective before and after surgery, for newborn prophylaxis, and again conjunctivitis and corneal infections. The use of this L.A. BioMed developed eye drop annually prevents thousands of eyes undergoing routine surgery from going blind.
Research Interest
Newborn prophylaxis, and again conjunctivitis and corneal infections
Publications
-
A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol
-
Continuous oxygen monitoring of the conjunctiva in neonates., J Perinatology
-
Monitoring Conjunctival pH, Carbon Dioxide, and Oxygen Tensions During Cardio-Pulmonary Bypass, Journal of ExtraCorporeal Technology
